Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu rev Microbiol. 1996;50:825–54.
Article
CAS
PubMed
Google Scholar
Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013;9:e1003211. doi:10.1371/journal.ppat.1003211.
Article
PubMed
PubMed Central
Google Scholar
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J med. 2011;365:493–505.
Article
CAS
PubMed
PubMed Central
Google Scholar
Diaz RSD, Vásquez VS. Infecção pelo HIV e terapia antirretroviral em 2012. Brasil: Permanyer Brasil Publicações; 2012.
Google Scholar
Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. Aids. 1993;7:1159–66.
Article
CAS
PubMed
Google Scholar
Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J med. 1995;332:201–8.
Article
CAS
PubMed
Google Scholar
Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406–16.
Article
CAS
PubMed
Google Scholar
Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053–6.
Article
PubMed
Google Scholar
Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563–71.
Article
PubMed
Google Scholar
Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of defense HIV natural history study. J Infect Dis. 2009;200:1714–23.
Article
PubMed
Google Scholar
Saag M, Deeks SG. How do HIV elite controllers do what they do? Clin Infect Dis. 2010;51:239–41.
Article
PubMed
Google Scholar
Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV med. 2007;15:134–6.
PubMed
Google Scholar
Sajadi MM, Constantine NT, Mann DL, Charurat M, Dadzan E, Kadlecik P, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009;50:403–8.
Article
PubMed
PubMed Central
Google Scholar
Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PLoS One. 2014;9:e86719. doi:10.1371/journal.pone.0086719.
Espíndola MS, Soares LS, Galvão-Lima LJ, Zambuzi FA, Cacemiro MC, Brauer VS, et al. HIV infection: focus on the innate immune cells. Immunol res. 2016;64:1118–32.
Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS. 2016;11:417–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Platten M, Jung N, Trapp S, Flossdorf P, Meyer-Olson D. Schulze Zur Wiesch J, et al. Cytokine and Chemokine Signature in Elite versus Viremic Controllers Infected with HIV AIDS res hum Retroviruses. 2016;32:579–87.
CAS
PubMed
Google Scholar
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para manejo da infecção. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais. – Brasília : Ministério da Saúde, 2015. Available: http://www.aids.gov.br/sites/default/files/anexos/publicacao/2013/55308/protocolofinal_31_7_2015_pdf_31327.pdf. Accessed 10 Sept 2016.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
ANRS Temprano 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J med. 2015;373:808–22.
Article
Google Scholar
Insight START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J med. 2015;373:795–807.
Article
Google Scholar
Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, Multicenter AIDS cohort study, Multicenter hemophilia cohort study, san Francisco City cohort, ALIVE study. Science. 1996;273:1856–62.
Article
CAS
PubMed
Google Scholar
Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE study, hemophilia growth and development study (HGDS), Multicenter AIDS cohort study (MACS), Multicenter hemophilia cohort study (MHCS), san Francisco City cohort (SFCC). Science. 1998;279:389–93.
Article
CAS
PubMed
Google Scholar
Ayres M, Ayres MJ, Ayres DL, Santos AS. BioEstat 5.0: aplicações estatísticas nas áreas das ciências biológicas e médicas. 5st ed. Editora Instituto de desenvolvimento sustentável Mamirauá; Brasília IDSM/MCT/CNPq, 2007.
Liu SL, Schacker T, Musey L, Shriner D, McElrath MJ, Corey L, et al. Divergent patterns of progression to AIDS after infection from the same source: HIV type 1 evolution and antiviral responses. J Virol. 1997;71:4284–95.
CAS
PubMed
PubMed Central
Google Scholar
Carrington M, Walker BD. Immunogenetics of spontaneous control of HIV. Annu rev med. 2012;63:131–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Okulicz JF. Elite Controllers and Long-term Nonprogressors: Models for HIV Vaccine Development? J AIDS Clinic Res. 2012. doi:10.4172/2155-6113.1000139.
Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia: extremes on a continuum. Aids. 2017;31:1091–8.
Article
CAS
PubMed
Google Scholar
Santos SEB, Guerreiro JF. The indigenous contribution to the formation of the population of the Brazilian Amazon region. Rev Bras Genet. 1995;18:311–5.
Google Scholar
Okulicz JF, Lambote O. Epidemiology and clinical characteristics of elite controllers. Current Opinion HIV AIDS. 2011;6:163–8.
Article
Google Scholar
Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, et al. Multiple origins of virus persistence during natural control of HIV infection. Cell. 2016;166:1004–15.
Article
CAS
PubMed
Google Scholar
Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984–90.
Article
PubMed
PubMed Central
Google Scholar
Côrtes FH, Passaes CP, Bello G, Teixeira SL, Vorsatz C, Babic D, et al. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J Acquir Immune Defic Syndr. 2015;68:377–85.
Article
PubMed
PubMed Central
Google Scholar
Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL. HIV med. 2006;7:383–8.
Article
CAS
PubMed
Google Scholar
Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis. 2007;195:425–31.
Article
PubMed
Google Scholar
Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012;18:449–58.
Article
CAS
PubMed
Google Scholar
Eholié SP, Badje A, Kouame GM, N'takpe JB, Moh R, Danel C, et al. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Res Ther. 2016. doi: 10.1186/s12981-016-0111-1.
Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature. 2012;491:129–33.
Article
CAS
PubMed
Google Scholar
Lécuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, et al. Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol. 2014;88:176–87.
Article
PubMed
PubMed Central
Google Scholar
Martins MA, Tully DC, Cruz MA, Power KA, Veloso de Santana MG, Bean DJ, et al. Vaccine-induced simian immunodeficiency virus-specific CD8+ T-cell responses focused on a single nef epitope select for escape variants shortly after infection. J Virol. 2015;89:10802–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yada Tansiri Y, Rowland-Jones SL, Ananworanich J, Hansasuta P. Clinical outcome of HIV Viraemic controllers and Noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppression. PLoS. 2015;10:e0118871. doi:10.1371/journal.pone.0118871.
Article
Google Scholar
Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French hospital database on HIV. Aids. 2009;23:1163–9.
Article
PubMed
Google Scholar
Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity. 2016;44:391–405.
Article
PubMed
Google Scholar
Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009. doi: 10.1136/bmj.a3172.
Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. Aids. 2009;23:1059–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol a Biol Sci med Sci. 2005;60:556–65.
Article
PubMed
Google Scholar
Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006;176:2645–53.
Article
CAS
PubMed
Google Scholar
Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing dev. 2006;127:695–704.
Article
CAS
PubMed
Google Scholar
Bernal Morell E, Serrano Cabeza J, Muñoz Á, Marín I, Masiá M, Gutiérrez F, et al. The CD4/CD8 ratio is inversely associated with carotid intima-media thickness progression in human immunodeficiency virus-infected patients on antiretroviral treatment. AIDS res hum Retrovir. 2016;32:648–53.
Article
CAS
PubMed
Google Scholar
Carvalhaes FAPL, Cardoso GL, Vallinoto ACR, Machado LF, Ishak MOG, Ishak R, et al. Frequencies of CCR5∆32, CCR2-64I and SDF1-3’A mutations in human immunodeficiency virus (HIV) seropositive subjects and seronegative individuals from the state of Pará in Brazilian Amazonia. Genet Mol Biol. 2005;28:665–9.
Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat med. 1996;2:405–11.
Article
CAS
PubMed
Google Scholar
Magierowska M, Theodorou I, Debré P, Sanson F, Autran B, Rivière Y, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood. 1999;93:936–41.
CAS
PubMed
Google Scholar
Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with gag-specific CD8 T cell responses. J Immunol. 2009;182:7828–37.
Article
PubMed
Google Scholar
Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330:1551–7.
Article
PubMed
PubMed Central
Google Scholar
Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811–5.
Article
CAS
PubMed
Google Scholar
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–7.
Article
CAS
PubMed
Google Scholar
Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One. 2012: e30881. doi: 10.1371/journal.pone.0030881.
Noel N, Boufassa F, Lécuroux C, Saez-Cirion A, Bourgeois C, Dunyach-Remy C, et al. Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids. 2014;28:467–76.
Article
CAS
PubMed
Google Scholar
Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids. 2004;18:981–9.
Article
PubMed
Google Scholar
Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–44.
Article
PubMed
Google Scholar
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200:973–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575–81.
Article
CAS
PubMed
Google Scholar
Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M, et al. Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood. 2009;113:6611–8.
Article
CAS
PubMed
Google Scholar
de Medeiros RM, Valverde-Villegas JM, Junqueira DM, Gräf T, Lindenau JD, de Mello MG, et al. Rapid and slow progressors show increased IL-6 and IL-10 levels in the pre-AIDS stage of HIV infection. PLoS One. 2016: e0156163. doi: 10.1371/journal.pone.0156163.
Hayashida T, Gatanaga H, Tanuma J, Oka S. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS res hum Retrovir. 2008;24:495–8.
Article
CAS
PubMed
Google Scholar
Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, et al. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J med Virol. 2009;81:1681–90.
Article
CAS
PubMed
Google Scholar
Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One. 2013: e55525. doi: 10.1371/journal.pone.0055525.
Williams A, Steffens F, Reinecke C, Meyer D. The Th1/Th2/Th17 cytokine profile of HIV-infected individuals: a multivariate cytokinomics approach. Cytokine. 2013;61:521–6.
Article
CAS
PubMed
Google Scholar
Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J med. 1995;332:209–16.
Article
CAS
PubMed
Google Scholar
Strathdee SA, Veugelers PJ, Page-Shafer KA, McNulty A, Moss AR, Schechter MT, et al. Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. Aids. 1996;10:959–65.
Article
CAS
PubMed
Google Scholar
Okulicz JF, Grandits GA, Weintrob AC, Landrum ML, Ganesan A, Crum-Cianflone NF, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis. 2010;50:1187–91.
Article
PubMed
Google Scholar
Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. Aids. 2010;24:1095–105.
Article
CAS
PubMed
PubMed Central
Google Scholar
López M, Soriano V, Peris-Pertusa A, Rallón N, Restrepo C, Benito JM. Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS res hum Retrovir. 2011;27:157–65.
Article
PubMed
Google Scholar
Sáez-Cirión A, Hamimi C, Bergamaschi A, David A, Versmisse P, Mélard A, et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood. 2011;118:955–64.
Article
PubMed
PubMed Central
Google Scholar
Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, Keh CE, et al. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood. 2012;119:745–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, et al. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunological response in later treatment. Aids. 2016;30:879–88.
Article
CAS
PubMed
PubMed Central
Google Scholar